Table 2 Summary of patient characteristics and demographics and change in BMD following discontinuation of etidronate or alendronate.

Age at Discontinuation (mean [SD])

64.3 [14.41]

69.4 [9.23]

Years on Treatment (mean [SD])

6.8 [2.21]

5.6 [1.03] *

Age at Menarche (mean [SD])

13.0 [1.664]

12.8 [2.49]

Number of years since menopause (mean [SD])

24.7 [9.18]

27.36 [9.04]

Milk Intake ≥ 1/2 pint/day (%)

15.8

6.25

Walking < 30 minutes/day

36.48

25

(%) > 1 hour/day

5.26

12.5

Previous fragility fracture(s) (%)

26.32

37.5

BMI (Kg/m²) (mean [SD])

25.47 [6.27]

26.48 [4.67]

Current and Ex-Smokers (%)

36.84

18.75

Alcohol Intake ≤ 14 units/week (%)

52.63

37.5

Positive Family History of Osteoporosis (%)

42.12

25

Lumbar Spine BMD at discontinuation (g/cm²) (mean [SD])

0.856 [0.118]

0.761 [0.106]

Lumbar Spine BMD after discontinuation (g/cm²) (mean [SD])

0.855 [0.107]

0.769 [0.106]

Total Hip BMD at discontinuation (g/cm²) (mean [SD])

0.794 [0.133]

0.739 [0.105]

Total Hip BMD after discontinuation (g/cm²) (mean [SD])

0.792 [0.129]

0.736 [0.099]